- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07392892
En studie for å lære om studiemedisinen PF-08634404 i kombinasjon med kjemoterapi ved gastroøsofageal kreft
EN FAZE 2/3 INTERVENSJONSTUDIE AV PF-08634404 I KOMBINASJON MED KEMOTERAPI BEHANDLINGSNAIVE DELTAKERE MED LOKALT AVANSERT ELLER METASTATISK MAKRE, GASTROESOFAGEALT KNUTEPUNKT ELLER SPISERØRSADENOKARSINOM
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-post: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Har ikke rekruttert ennå
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
California
-
Atascadero, California, Forente stater, 93422
- Rekruttering
- UCLA Hematology/Oncology - Atascadero
-
Burbank, California, Forente stater, 91505
- Rekruttering
- UCLA Hematology/Oncology - Burbank
-
Encino, California, Forente stater, 91436
- Rekruttering
- UCLA Hematology/Oncology - Encino
-
Marina del Rey, California, Forente stater, 90292
- Rekruttering
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch, California, Forente stater, 91326
- Rekruttering
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco, California, Forente stater, 94158
- Har ikke rekruttert ennå
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco, California, Forente stater, 94158
- Har ikke rekruttert ennå
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo, California, Forente stater, 93401
- Rekruttering
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara, California, Forente stater, 93101
- Rekruttering
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica, California, Forente stater, 90404
- Rekruttering
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Boulder, Colorado, Forente stater, 80303
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Centennial, Colorado, Forente stater, 80112
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Forente stater, 80907
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Forente stater, 80923
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Forente stater, 80220
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Englewood, Colorado, Forente stater, 80113
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Lakewood, Colorado, Forente stater, 80228
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Littleton, Colorado, Forente stater, 80120
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree, Colorado, Forente stater, 80124
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Longmont, Colorado, Forente stater, 80504
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Pueblo, Colorado, Forente stater, 81003
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Thornton, Colorado, Forente stater, 80260
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach, Florida, Forente stater, 32117
- Har ikke rekruttert ennå
- Florida Cancer Specialists
-
Fleming Island, Florida, Forente stater, 32003
- Har ikke rekruttert ennå
- Florida Cancer Specialists
-
Palm Beach Gardens, Florida, Forente stater, 33410
- Har ikke rekruttert ennå
- Florida Cancer Specialists
-
Sebring, Florida, Forente stater, 33870
- Har ikke rekruttert ennå
- Florida Cancer Specialists
-
Wellington, Florida, Forente stater, 33414
- Har ikke rekruttert ennå
- Florida Cancer Specialists
-
West Palm Beach, Florida, Forente stater, 33401
- Har ikke rekruttert ennå
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights, Illinois, Forente stater, 60005
- Rekruttering
- Illinois Cancer Specialists
-
Bloomington, Illinois, Forente stater, 61704
- Rekruttering
- Illinois CancerCare - Bloomington
-
Chicago, Illinois, Forente stater, 60631
- Rekruttering
- Illinois Cancer Specialists
-
Galesburg, Illinois, Forente stater, 61401
- Rekruttering
- Illinois CancerCare - Galesburg
-
Niles, Illinois, Forente stater, 60714
- Rekruttering
- Illinois Cancer Specialists
-
Ottawa, Illinois, Forente stater, 61350
- Rekruttering
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin, Illinois, Forente stater, 61554
- Rekruttering
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forente stater, 61615
- Rekruttering
- Illinois CancerCare, P.C.
-
Peru, Illinois, Forente stater, 61354
- Rekruttering
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington, Illinois, Forente stater, 61571
- Rekruttering
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis, Maryland, Forente stater, 21401
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Bethesda, Maryland, Forente stater, 20817
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Brandywine, Maryland, Forente stater, 20613
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Columbia, Maryland, Forente stater, 21044
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Germantown, Maryland, Forente stater, 20876
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Largo, Maryland, Forente stater, 20774
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Rockville, Maryland, Forente stater, 20850
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Silver Spring, Maryland, Forente stater, 20904
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno, Nevada, Forente stater, 89502
- Rekruttering
- Renown Regional Medical Center
-
Reno, Nevada, Forente stater, 89502
- Rekruttering
- Renown Health Medical Oncology
-
Reno, Nevada, Forente stater, 89502
- Rekruttering
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07960
- Har ikke rekruttert ennå
- Atlantic Health System
-
Summit, New Jersey, Forente stater, 07901
- Har ikke rekruttert ennå
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City, New York, Forente stater, 11101
- Rekruttering
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City, New York, Forente stater, 11101
- Rekruttering
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York, New York, Forente stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York, New York, Forente stater, 10021
- Rekruttering
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York, New York, Forente stater, 10022
- Rekruttering
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45245
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Forente stater, 45242
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Forente stater, 45211
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield, Ohio, Forente stater, 45014
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem, Pennsylvania, Forente stater, 19020
- Rekruttering
- Alliance Cancer Specialists, PC
-
Doylestown, Pennsylvania, Forente stater, 18901
- Rekruttering
- Alliance Cancer Specialists, PC
-
Horsham, Pennsylvania, Forente stater, 19044
- Rekruttering
- Alliance Cancer Specialists, PC
-
Langhorne, Pennsylvania, Forente stater, 19047
- Rekruttering
- Alliance Cancer Specialists, PC
-
Media, Pennsylvania, Forente stater, 19063
- Rekruttering
- Alliance Cancer Specialists, PC
-
Sellersville, Pennsylvania, Forente stater, 18960
- Rekruttering
- Alliance Cancer Specialists, PC
-
Wynnewood, Pennsylvania, Forente stater, 19096
- Rekruttering
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving, Texas, Forente stater, 75063
- Rekruttering
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington, Virginia, Forente stater, 22201
- Rekruttering
- Virginia Cancer Specialists, PC
-
Chesapeake, Virginia, Forente stater, 23320
- Rekruttering
- Virginia Oncology Associates
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Virginia Cancer Specialists, PC
-
Hampton, Virginia, Forente stater, 23666
- Rekruttering
- Virginia Oncology Associates
-
Manassas, Virginia, Forente stater, 20110
- Rekruttering
- Virginia Cancer Specialists, PC
-
Newport News, Virginia, Forente stater, 23606
- Rekruttering
- Virginia Oncology Associates
-
Norfolk, Virginia, Forente stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
Reston, Virginia, Forente stater, 20190
- Rekruttering
- Virginia Cancer Specialists, PC
-
Virginia Beach, Virginia, Forente stater, 23456
- Rekruttering
- Virginia Oncology Associates
-
Woodbridge, Virginia, Forente stater, 22191
- Rekruttering
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- Rekruttering
- University of Washington Medical Center
-
Seattle, Washington, Forente stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Forente stater, 98104
- Rekruttering
- Harborview Medical Center
-
-
-
-
-
Paris, Frankrike, 75015
- Rekruttering
- Hôpital Européen Georges Pompidou
-
-
-
-
Central District
-
Petah Tikva, Central District, Israel, 4941492
- Rekruttering
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, Israel, 5265601
- Rekruttering
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv, TELL ABĪB, Israel, 6423906
- Rekruttering
- Sourasky Medical Center
-
-
-
-
-
Milan, Italia, 20141
- Rekruttering
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Rekruttering
- Aichi Cancer Center
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510655
- Rekruttering
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan, Hubei, Kina, 430079
- Rekruttering
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200031
- Rekruttering
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- Sichuan Cancer hospital
-
-
-
-
-
Bayamón, Puerto Rico, 00959
- Rekruttering
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati, United States, Puerto Rico, 00674
- Rekruttering
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Spania, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spania, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense, Ourense [orense], Spania, 32005
- Har ikke rekruttert ennå
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
-
Tainan, Taiwan, 704302
- Rekruttering
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- Rekruttering
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Rekruttering
- Taipei Veterans General Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andre navn:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Eksperimentell: Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andre navn:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Aktiv komparator: Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
Tidsramme: Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fase 2: Forekomst av anti-legemiddel-antistoff (ADA) mot PF-08634404
Tidsramme: Omtrent 21 måneder
|
Omtrent 21 måneder
|
|
|
Fase 3: Forekomst av ADA mot PF-08634404
Tidsramme: Omtrent 21 måneder
|
Omtrent 21 måneder
|
|
|
Fase 3: Endring fra utgangspunkt i Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) totalscore
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
|
|
Fase 3: Tid til definitiv forverring i FACT-Ga totalpoengsum
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
|
|
Fase 3: Tid til definitiv forverring i Gastric Cancer Subscale (GaCS)-skår
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
Tidsramme: Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Tidsramme: Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Neoplasmer i magen
- Adenokarsinom i spiserøret
- Aminosyrer, peptider og proteiner
- Proteiner
- Terapeutikk
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Nivolumab
- Medikamentell terapi
Andre studie-ID-numre
- C6461016
- 2025-524717-86-00 (Registeridentifikator: CTIS (EU))
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .